| HOME >> BIOLOGY >> TECHNOLOGY |
21,639,793$
27,199,045LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable$
445,515$
3,128,203Accrued expenses and other liabilities3,245,9903,035,284Total current liabilities3,691,5056,163,487Other long-term liabilities454,093461,858Derivative instruments2,956,0808,362,995Total liabilities7,101,67814,988,340Stockholders' equity:Common stock, $0.0001 par value; 100,000,000 shares authorized; 48,194,035 and 46,238,244 shares issued and outstanding at September 30, 2011 and December 31, 2010, respectively4,8194,624Additional paid-in-capital207,810,326200,847,468Accumulated other comprehensive income1,161,6201,250,497Accumulated deficit(194,438,650)(189,891,884)Total stockholders'
equity14,538,11512,210,705Total liabilities and stockholders' equity$
21,639,793$
27,199,045PHARMATHENE, INC.UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSThree months endedSeptember 30,Nine months endedSeptember 30,2011201020112010Contract revenue$
5,260,057$
6,243,567$
18,026,619$
14,139,711Operating expenses:Research and development4,884,2316,172,14716,688,70317,064,900General and administrative3,283,2463,177,88811,632,27212,625,132Depreciation and amortization114,494258,231348,813757,929Total operating expenses8,281,9719,608,26628,669,78830,447,961Loss from operations(3,021,914)(3,364,699)(10,643,169)(16,308,250)Other income (expenses):Interest income3,96118410,4966,249Interest expense(9,932)(946,023)(40,540)(2,815,638)Other income (expense)95,520(93,260)50,89275,914Change in market value of derivative instruments2,898,86975,5946
'/>"/>
| SOURCE PharmAthene, Inc. Copyright©2010 PR Newswire. All rights reserved |